No Data
No Data
Baxter Issues Update on Supply Issues Caused by Hurricane Helene
Impact of Natural Disasters and Muted Growth on Fresenius Medical Care: Reiterating an Underperform Rating
Fresenius Eyes Increased Production to Address Potential US Drug Shortage
Truist Financial Maintains Fresenius Medical Care(FMS.US) With Hold Rating, Raises Target Price to $23
Dialysis Services Focused Insights Report 2024-2029 Featuring Key Vendors - B. Braun, Baxter, DaVita, Dialysis Clinic (DCI), Fresenius Medical Care, Innovative Renal Care, and NephroPlus - ResearchAndMarkets.com
Fresenius Medical Care (ETR:FME) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Advances 4.8% This Past Week
No Data
No Data